3B BlackBio Dx Ltd
3BBLACKBIO.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.44B
Close$
$2323.93
74.3% upside
Current Fair Value
74.3% upsideUndervalued by 74.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.44 Billion |
|---|---|
| Enterprise Value | $11.43 Billion |
| Dividend Yield | $5.00 (0.38%) |
| Earnings per Share | $0.75 |
| Beta | 0.42 |
| Outstanding Shares | 8,582,670 |
Return
| Return on Equity | 17.49% |
|---|---|
| Return on Assets | 15.01% |
| Return on Invested Capital | 14.21% |
Valuation & Multiples
| P/E Ratio | 19.77 |
|---|---|
| PEG | -61.67 |
| Price to Sales | 1332.95 |
| Price to Book Ratio | 333.24 |
| Enterprise Value to Revenue | 682.44 |
| Enterprise Value to EBIT | 2190.87 |
| Enterprise Value to Net Income | 1872 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About 3B BlackBio Dx Ltd
86 employees
CEO: Dhirendra Kuber Dubey Established in 1972 and headquartered in Bhopal, India, 3B Blackbio Dx Limited specializes in the conception, production, and market distribution of sophisticated molecular diagnostic technologies. The company's core focus is on deliveri...